[{"abstract": "The continuing turmoil in Twitter\u2019s executive suite, a hallmark of the company\u2019s eight-year existence, suggests that the company is struggling in the face of stiffening competition from Facebook.", "web_url": "https://www.nytimes.com/2014/07/02/technology/recent-leadership-changes-suggest-that-twitter-is-failing-to-find-its-footing.html", "snippet": "The continuing turmoil in Twitter\u2019s executive suite, a hallmark of the company\u2019s eight-year existence, suggests that the company is struggling in the face of stiffening competition from Facebook.", "lead_paragraph": "SAN FRANCISCO \u2014 Twitter\u2019s chief executive, Dick Costolo, has replaced virtually every crucial executive at the company in the last few months as he has struggled to figure out how to get more people using the service.", "print_section": "B", "print_page": "1", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/02/business/TWITTER/TWITTER-articleLarge.jpg", "height": 361, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/07/02/business/TWITTER/TWITTER-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 361}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/02/business/TWITTER/TWITTER-jumbo.jpg", "height": 616, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/02/business/TWITTER/TWITTER-superJumbo.jpg", "height": 1231, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/02/business/TWITTER/TWITTER-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/07/02/business/TWITTER/TWITTER-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/02/business/TWITTER/TWITTER-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Twitter\u2019s Revolving Door Spins Again", "kicker": null, "content_kicker": null, "print_headline": "Twitter\u2019s Revolving Door Spins Again", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Appointments and Executive Changes", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Twitter", "rank": 4, "major": "N"}, {"name": "persons", "value": "Costolo, Dick", "rank": 5, "major": "N"}, {"name": "persons", "value": "Noto, Anthony J", "rank": 6, "major": "N"}], "pub_date": "2014-07-02T00:58:49+0000", "document_type": "article", "news_desk": "Business", "section_name": "Technology", "byline": {"original": "By Vindu Goel and Mike Isaac", "person": [{"firstname": "Vindu", "middlename": null, "lastname": "Goel", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}, {"firstname": "Mike", "middlename": null, "lastname": "Isaac", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 2}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/9110da01-306e-51a0-88b6-ba31d3387a4f", "word_count": 1168, "uri": "nyt://article/9110da01-306e-51a0-88b6-ba31d3387a4f"}, {"abstract": "A unit of the Swiss drug maker Roche is acquiring the biotechnology firm based in San Diego, Calif., that was spun off from Aragon Pharmaceuticals last year.", "web_url": "https://dealbook.nytimes.com/2014/07/02/roche-to-pay-up-to-1-7-billion-for-seragon-pharmaceuticals/", "snippet": "A unit of the Swiss drug maker Roche is acquiring the biotechnology firm based in San Diego, Calif., that was spun off from Aragon Pharmaceuticals last year.", "lead_paragraph": "LONDON \u2013 The Swiss drug maker Roche Group said on Wednesday that it would pay up to $1.7 billion to acquire Seragon Pharmaceuticals, a privately held biotechnology firm focused on developing treatments for breast cancer.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/03/business/international/03roche/03roche-articleLarge.jpg", "height": 391, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/07/03/business/international/03roche/03roche-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 391}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/03/business/international/03roche/03roche-jumbo.jpg", "height": 667, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/03/business/international/03roche/03roche-superJumbo.jpg", "height": 1334, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/03/business/international/03roche/03roche-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/07/03/business/international/03roche/03roche-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/07/03/business/international/03roche/03roche-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Roche to Pay Up to $1.7 Billion for Seragon Pharmaceuticals", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Biotechnology", "rank": 1, "major": "N"}, {"name": "subject", "value": "Clinical Trials", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 4, "major": "N"}, {"name": "persons", "value": "Scheller, Richard H", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Genentech Inc", "rank": 6, "major": "N"}, {"name": "organizations", "value": "Johnson & Johnson", "rank": 7, "major": "N"}, {"name": "organizations", "value": "Roche Holding A G", "rank": 8, "major": "N"}, {"name": "glocations", "value": "Basel (Switzerland)", "rank": 9, "major": "N"}, {"name": "glocations", "value": "San Diego (Calif)", "rank": 10, "major": "N"}, {"name": "glocations", "value": "San Francisco (Calif)", "rank": 11, "major": "N"}], "pub_date": "2014-07-02T08:15:51+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Chad Bray", "person": [{"firstname": "Chad", "middlename": null, "lastname": "Bray", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/234002a3-2cbc-5def-a872-149f263255d4", "word_count": 301, "uri": "nyt://article/234002a3-2cbc-5def-a872-149f263255d4"}]